MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$1,338K
EPS
-$0.98
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-06-30
2025-03-31
2024-09-30
2024-06-30
Revenues
0
-
10
4
Selling, general and administrative expense
-
-
1,237
1,625
Revenues-Clinical Trial Supply
0
-
-
-
Research and development
68
822
950
2,023
General and administrative
1,249
4,214
-
-
Total operating expenses
1,317
5,036
2,187
3,648
Operating loss
-1,317
-5,036
-2,177
-3,644
Other income, net
2
10
-
-
Amount before accretion (amortization) of purchase discount (premium) of interest income expense on nonoperating securities
-
-
8
-28
Interest income
2
6
-
-
Foreign exchange losses
-3
-8
2
3
Gain on deconsolidation of subsidiary
0
4,947
-
-
Total other income (expense), net
1
4,955
10
-25
Loss before taxes
-1,316
-81
-2,167
-3,669
Income tax benefit
2
-
-210
-412
Net loss
-1,318
-81
-1,957
-3,257
Dividend on convertible exchangeable preferred shares
20
-
-
-
Net income (loss) available to common stockholders, diluted, total
-
-
-1,957
-3,257
Net loss applicable to common shareholders
-1,338
-81
-
-
Basic EPS
-0.98
0
-0.18
-0.72
Diluted EPS
-0.98
0
-
-0.72
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss applicable
to common...
-$1,338K
Net loss
-$1,318K
(59.53%↑ Y/Y)
Dividend on convertible
exchangeable preferred...
$20K
Interest income
$2K
Other income, net
$2K
Loss before taxes
-$1,316K
(64.13%↑ Y/Y)
Income tax benefit
$2K
(100.49%↑ Y/Y)
Total other income
(expense), net
$1K
(104.00%↑ Y/Y)
Foreign exchange losses
-$3K
(-200.00%↓ Y/Y)
Operating loss
-$1,317K
(63.86%↑ Y/Y)
Total operating
expenses
$1,317K
(-63.90%↓ Y/Y)
General and
administrative
$1,249K
Research and development
$68K
(-96.64%↓ Y/Y)
Buy us a coffee
Cyclacel Pharmaceuticals, Inc. (CYCC)
Cyclacel Pharmaceuticals, Inc. (CYCC)